Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Dean Investment Associates LLC

Dean Investment Associates LLC reduced its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 31.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,280 shares of the company's stock after selling 4,181 shares during the period. Dean Investment Associates LLC's holdings in Henry Schein were worth $642,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of HSIC. Lyrical Asset Management LP purchased a new stake in shares of Henry Schein during the 4th quarter valued at $126,655,000. Norges Bank purchased a new stake in shares of Henry Schein during the fourth quarter valued at approximately $103,301,000. National Bank of Canada FI boosted its holdings in Henry Schein by 102.4% in the fourth quarter. National Bank of Canada FI now owns 1,084,511 shares of the company's stock valued at $75,048,000 after acquiring an additional 548,561 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Henry Schein during the fourth quarter valued at $34,720,000. Finally, Clarkston Capital Partners LLC increased its holdings in shares of Henry Schein by 24.8% during the fourth quarter. Clarkston Capital Partners LLC now owns 1,744,225 shares of the company's stock valued at $120,700,000 after acquiring an additional 346,420 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Trading Up 0.8 %

Shares of NASDAQ HSIC traded up $0.51 during trading on Wednesday, reaching $65.05. The company had a trading volume of 287,087 shares, compared to its average volume of 1,608,518. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company's fifty day moving average price is $69.87 and its 200-day moving average price is $71.88. The stock has a market cap of $7.97 billion, a P/E ratio of 26.77, a PEG ratio of 2.13 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. Henry Schein's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the company posted $0.66 earnings per share. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Insider Buying and Selling at Henry Schein

In related news, Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. This trade represents a 9.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. StockNews.com cut shares of Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Barrington Research reissued an "outperform" rating and issued a $90.00 price objective on shares of Henry Schein in a research note on Wednesday, February 26th. Jefferies Financial Group upped their target price on Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a research report on Thursday, January 23rd. UBS Group decreased their target price on Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 26th. Finally, Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and boosted their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Henry Schein has a consensus rating of "Moderate Buy" and an average target price of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.